Timber Pharmaceuticals — Investor Presentation (December 2021)
30 slides from Timber Pharmaceuticals's investor presentation, Dec 8, 2021
Slide 1: Building Bridges in Medical Dermatology
Building Bridges in Medical Dermatology Investor Presentation December 2021 NYSE American: TMBR
Slide 2: Safe Harbor Statement
NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut
Slide 3: Timber Pharmaceuticals Overview
NYSE American: TMBR Timber Pharmaceuticals Overview 3 3 NYSE American: TMBR Timber Pharmaceuticals is a specialty pharmaceutical company devoted to transforming the lives of patients with rare, high impact dermatologic diseases by utilizing advanced translational science The company’s investigationa
Slide 4: Investment Highlights
NYSE American: TMBR Investment Highlights 4 • Positioned to become a leading rare disease dermatology company with a focus on rare and orphan diseases, led by a management team with a proven track record in development and commercialization • High potential multi - product candidate pipeline • Prove
Slide 5: Timber Business Model
NYSE American: TMBR Timber Business Model 5 Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Timber can be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires potentially smaller and less costly drug trials with greater fl
Slide 6: Strategic Pipeline in Rare Dermatologic Disease
NYSE American: TMBR Strategic Pipeline in Rare Dermatologic Disease 6
Slide 7: Life Cycle Management
NYSE American: TMBR Life Cycle Management 7 Market expansion potential for additional indications for all products TMB - 001 TMB - 002 TMB - 003 Darier’s Disease Sturge - Weber Syndrome Digital Ulcers in Scleroderma Severe Acne Port Wine Stains Hypertrophic/Keloid Scars
Slide 8: Unmet Need for Congenital Ichthyosis
NYSE American: TMBR Unmet Need: An efficacious and safe treatment that can be used long term to cover a large body surface area . 8 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis h
Slide 9: Topical Isotretinoin in CI
NYSE American: TMBR 9 TMB - 001 Topical Isotretinoin in CI Patented topical formulation minimizing systemic absorption and allowing for chronic treatment Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where
Slide 10: Topical Isotretinoin in CI Phase IIb Study Design (CONTROL Study)
NYSE American: TMBR 10 TMB - 001 Topical Isotretinoin in CI Phase IIb Study Design (CONTROL Study) Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB - 001 for Treatment of Congenital Ichthyosis Primary Objective Proportion of subjects with Visual Index of Ichthyosis Sev
Slide 11: CONTROL Study - Efficacy Per Protocol
NYSE American: TMBR 11 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus
Slide 12: CONTROL Study - Efficacy Intent to Treat (ITT)
NYSE American: TMBR 12 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the ITT Population in 0.05% dose achieved a 2 point reduction in IGA versus 8% in the
Slide 13: CONTROL Study - Lamellar Ichthyosis Responder Patient
NYSE American: TMBR 13 TMB - 001 CONTROL Study - 21 yr. old patient with Lamellar Ichthyosis (ALOX12B) - 0.05% arm (responder) End Of Study – Visit 6 Baseline
Slide 14: TMB-002 for Facial Angiofibromas in Tuberous Sclerosis Complex
NYSE American: TMBR 14 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of ha
Slide 15: TMB-002 Topical Rapamycin (Pascomer)
NYSE American: TMBR 15 TMB - 002 Topical Rapamycin ( Pascomer ®) Potentially the First Commercially Available, High - Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in preclinical toxici
Slide 16: TMB-002 Topical Rapamycin (Pascomer) Study Design
NYSE American: TMBR 16 TMB - 002 Topical Rapamycin ( Pascomer ®) Title Dose - Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibromas Associated With Tuberous Sclerosis Complex Primary Objective Proportion of subjects with IGA treatment success defined as clear or almos
Slide 17: TMB-003 Topical Sitaxsentan for Sclerotic Skin Diseases
NYSE American: TMBR 17 TMB - 003 Topical Sitaxsentan for Sclerotic Skin Diseases Highly Selective ET - A inhibitor Sitaxsentan is a highly selective (6,500:1) ET - A receptor antagonist. • It was previously on the market in the EU, Canada and Australia as an oral treatment for PAH but was voluntaril
Slide 18: Lichen Sclerosis
NYSE American: TMBR 18 Lichen Sclerosis Rare chronic disease of vulvae and perianal areas which affects approximately 160,000 women in the US* Lichen Sclerosis affects both sexes, but is predominant in women • Prevalence 0.1 - 1.7% of women; diagnosed more by gynecologists than dermatologists • Bimo
Slide 19: Scleroderma
NYSE American: TMBR 19 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in t
Slide 20: Barriers to Entry
NYSE American: TMBR Barriers to Entry 20 Orphan exclusivity granted for all three strategic assets • 7 years in U.S., 10 years in E.U. and Japan Patents granted and pending globally Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidation, tempera
Slide 21: Significant Clinical Milestones on a Quarterly Basis over next 12 months
NYSE American: TMBR Significant Clinical Milestones on a Quarterly Basis over next 12 months 21 TMB - 001 TMB - 002 Q4 2021 Topline Data for Phase IIb Trial Completed Enrollment of Phase IIb Q1 2022 End of Phase II FDA Meeting Broad Phase IIb Data Dissemination Q2 2022 Anticipated Start of Phase III
Slide 22: World Class Clinical Advisors and Partners
NYSE American: TMBR World Class Clinical Advisors and Partners 22 • Peter Elias, MD Professor, Dept of Dermatology, University of California, San Francisco (UCSF) • Keith Choate, MD, PhD Professor of Dermatology, Pathology, and Genetics, Yale University • Joyce Teng, MD Professor and Director of Ped
Slide 23: John Koconis, Chairman and CEO; Alan Mendelsohn, CMO
NYSE American: TMBR John Koconis, MBA, Chairman and CEO • Seasoned Pharmaceutical executive with over 25 years experience leading successful teams in global markets and having launche d multiple market leading products in Dermatology • President & CEO of LEO Pharma (US), established a market leading
Slide 24: Zachary Rome, Co-Founder, Director and COO; Joseph Lucchese, CFO
NYSE American: TMBR Zachary Rome, Co - Founder, Director and COO • Biopharmaceutical inventor and entrepreneur • Co - founder and President at Patagonia Pharmaceuticals, raised >$11 million in funding and advanced lead development candidate fr om concept to Phase IIb clinical studies • Recipient and
Slide 25: Independent Board of Directors
NYSE American: TMBR Independent Board of Directors 25 Lead Independent Board Member Respected expert in SEC reporting and internal controls with extensive financial leadership experience as CFO at several public life sciences companies. Independent Board Member Professor of Dermatology at New York U
Slide 26: Key Takeaways
NYSE American: TMBR Key Takeaways 26 Rare, High Need Medical Dermatology Large Market Potential Multiple Shots on Goal De - Risked Portfolio Management Expertise • High unmet needs with large market potential • All strategic programs have been granted Orphan Drug status • No approved treatments for
Slide 27: For additional Investor Information please contact
www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 NYSE American: TMBR
Slide 28: APPENDIX/Additional Slides
www.timberpharma.com APPENDIX/Additional Slides NYSE American: TMBR
Slide 29: Topical Isotretinoin in CI
NYSE American: TMBR 29 TMB - 001 Topical Isotretinoin in CI Baseline Day 57 Day 84 2 3 1 Vehicle TMB - 001 (0.1%) TMB - 001 (0.1%) TMB - 001 (0.1%) Percent of Subjects Achieving a 2 - point Reduction on Day 57 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% IGA Scaling Vehicle Active 0.1% Primary measure was
Slide 30: Condensed Balance Sheet September 30, 2021
NYSE American: TMBR Condensed Balance Sheet 30 September 30, 2021 Cash* $3,357,136 Other Current Assets $338,200 Total Current Assets $3,695,336 Other Assets $857,448 Total Assets $4,552,784 Total Current Liabilities $2,016,151 Long - Term Debt -- Lease Liability $419,683 Other Liabilities $149,297
Timber Pharmaceuticals — Investor Presentation (December 2021) on 6ix